Porcine colonic spirochetosis is a nonfatal diarrheal disease that affects pigs during the growing and finishing stages of production. The disease is caused by Serpulina pilosicoli, a newly recognized species of pathogenic intestinal spirochete. Antimicrobial therapy aimed at reducing the infection may be helpful in controlling spirochetal diarrhea. In this study, the in vitro antimicrobial susceptibilities of the reference isolate S. pilosicoli P43/6/78 from the United Kingdom and 19 field isolates obtained from pigs in Canada (n ϭ 5) and the United States (n ϭ 14) were determined against the antimicrobial agents carbadox, gentamicin, lincomycin, and tiamulin, all of which are commonly used for control of the related pathogenic intestinal spirochete S. hyodysenteriae. Additionally, the susceptibility or resistance of each isolate against each antimicrobial agent was estimated on the basis of available data on the in vitro antimicrobial susceptibility breakpoints of S. hyodysenteriae. Each isolate was identified on the basis of phenotypic and genotypic markers, and the minimum inhibitory concentration of each antimicrobial agent was determined by the agar-dilution method. All the isolates were susceptible to carbadox and tiamulin. The percentages of isolates susceptible, intermediate, and resistant to lincomycin were 42.1%, 42.1%, and 15.8%, respectively. Slightly less than half of the isolates (47.4%) were susceptible to gentamicin, and the remainder (52.6%) were resistant. Implementation of rational control measures to reduce infection by S. pilosicoli should improve overall health and productivity in swine herds.
Until recently, porcine hemolytic intestinal spirochetes consisted of 2 taxonomically recognized species in the genus Serpulina: the strongly ␤-hemolytic spirochete Serpulina hyodysenteriae, the agent of swine dysentery, and the weakly ␤-hemolytic intestinal spirochete (WBHIS) S. innocens, a nonpathogenic spirochete of the swine colon. 7, 13, 31 However, an association between a WBHIS, recently classified as S. pilosicoli, and a nonfatal diarrheal disease of growing pigs, called porcine intestinal spirochetosis or porcine colonic spirochetosis (PCS), has been recognized. 1, [5] [6] [7] [8] [9] [10] [11] [12] 19, [24] [25] [26] [27] [28] [32] [33] [34] [35] [36] [37] With more intensive swine production, where the efficiency of weight gain is closely monitored, PCS has been recognized as a major contributing factor to reduced performance in growing and finishing pigs. 5, 6, 8, 9, 10, 12, 34 Koch's postulates for S. pilosicoli have been fulfilled using gnotobiotic pigs 25 and conventional pigs. 3, 5, [33] [34] [35] Conventional pigs challenge exposed with S. pilosicoli have diarrhea and reduced performance as a result of colonization and inflammation of the cecum and colon. 3, 5, [33] [34] [35] Clinical signs of S. pilosicoli infection consist of diarrhea, which is transient to persistent. The feces from diarrheic pigs are watery to mucoid in consistency, green to cement gray in color, and without blood. The diarrhea usually occurs within 10-14 days after mixing grower pigs from different sources. 1, 5, 6, 9, 12, [33] [34] [35] Up to 50% of affected pigs may show diarrhea, but morbidity differs among farms. The factors responsible for this variation are incompletely understood, but diet form (pelleted vs. meal) and diet ingredients may be involved in modulating the onset and severity of PCS. 34, 35 Also, variations in the enteropathogenicity of S. pilosicoli have been demonstrated using a chick model. 23, 24 These factors may explain differences in the prevalence of diarrhea and reduction in the performance of pigs affected with PCS on different farms. Diarrhea associated with PCS usually subsides, but a concurrent reduction in weight gain results in pigs of uneven sizes within affected groups. This is a major problem for all-in/all-out management systems, in which PCS causes disruption of pig flow by extending the marketing period and increasing the number of pigs with lighter weights.
Antimicrobial therapy may be helpful in controlling spirochetal diarrhea. There have been several reports on the in vitro susceptibility of S. hyodysenteriae 2,8,9,14-17,20 -22,29,30,38,39 and some other uncharacterized WBHIS 8, 9, 14, 21, 29, 30 to selected antimicrobial agents. Because S. pilosicoli is a newly recognized intestinal spirochete, there is a need to determine the in vitro antimicrobial susceptibility of this organism so that disease-specific control strategies can be implemented. Preliminary reports on the in vitro activity of antimicrobial agents against a few Australian and Swedish North Carolina North Carolina IV/ND IV/ND ND ND 4/5, this report 4/5, this report * All isolates are from different farms except for isolates UNL-51 and UNL-52, isolates UNL-53 and UNL-54, isolates UNL-56 and UNL-57, and isolates UNL-58 and UNL-59 which were obtained from the same sampling on the same farm, and isolates T9300098 and T9301604B which were obtained from different samplings on the same farm approximately 10 mo apart. † Phenotype 10 and multilocus enzyme electrophoresis (MEE) type. 19 isolates of porcine S. pilosicoli suggest that antimicrobial susceptibility of S. pilosicoli is similar to that of S. hyodysenteriae. 8, 9, 36, 37 In the present study, the in vitro antimicrobial susceptibilities of the reference isolate S. pilosicoli P43/6/78 from the United Kingdom and 19 isolates obtained from pigs in Canada (n ϭ 5) and the United States (n ϭ 14) were determined for carbadox, gentamicin, lincomycin, and tiamulin, four antimicrobials commonly used for control of the closely related pathogenic intestinal spirochete, S. hyodysenteriae. Additionally, the susceptibility or resistance of each isolate against each antimicrobial agent was estimated on the basis of available data for the in vitro antimicrobial susceptibility breakpoints of S. hyodysenteriae. The field isolates were identified on the basis of phenotypic and genotypic markers, including a S. pilosicoli-specific 16S ribosomal RNA (rRNA) genebased polymerase chain reaction (PCR) assay. 24 The minimum inhibitory concentration (MIC) of each antimicrobial agent was determined by the agar-dilution method. 14 All the isolates were susceptible to carbadox and tiamulin; whereas, the suceptibility to lincomycin and gentamicin differed among the isolates.
Materials and methods
Bacterial strains and growth conditions. The sources, origins, and current classifications of reference and field isolates of S. pilosicoli used in this study are described in Table  1 . Strains UNL-51 to UNL-59 were isolated from rectal swabs obtained from diarrheic pigs within 2 wk after arrival on grower farms. 5 Isolates UNL-51 and UNL-52, UNL-53 and UNL-54, UNL-56 and UNL-57, and UNL-58 and UNL-59 were obtained from the same sampling on the same farm. Isolates T9300098 and T9301604B were obtained from different samplings on the same farm approximately 10 mo apart. All other isolates were from different farms. Primary isolation of the spirochetes was done by anaerobic culture on colistin, vancomycin, and spectinomycin selective medium. 7 Pure cultures of spirochetes were propagated on trypticase soy agar (TSA) with 5% citrated sheep blood (TSA-SB) or bovine blood (TSA-BB) incubated at 42 C in a commercial anaerobic culture system a or in prereduced anaerobically sterilized trypticase soy broth as previously de- scribed. 7, 18 Broth cultures were grown to late logarithmic phase (approximately 10 8 cells/ml) in 5-ml volumes, using Hungate tubes, and stirred constantly at 37 C under an atmosphere of 10% hydrogen, 10% carbon dioxide, and 80% nitrogen.
Genotypic characterization. The chromosomal DNA of the spirochetes was isolated using a previously described method. 28 An S. pilosicoli-specific 16S rRNA gene sequence was amplified using a modification 24 of a previously described method. 26 A 21-base forward primer extending from base position 65 of S. pilosicoli isolate P43/6/78 16S rRNA gene b (5Ј-AGAGGAAAGTTTTTTCGCTTC-3Ј) and a 20base Serpulina spp. conserved 16S rRNA gene reverse primer at position 506 (5Ј-TCCGCCTACTCACCCTTTAC-3Ј) were used. Negative controls consisting of samples with DNA from S. hyodysenteriae, S. innocens, or no template DNA were included in all assays. The DNA was amplified, using a thermocycler c in a total volume of 50 l containing 6 mM MgCl 2 , 1ϫ PCR buffer, 0.4 mM each dATP, dTTP, dGTP, and dCTP, c 100 pmol of primers, and 1.5 U Taq DNA polymerase in sterile filtered autoclaved water. Initial denaturing was for 10 min at 94 C, followed by 35 cycles (45 sec at 55 C, 45 sec at 72 C, 90 sec at 94 C). The amplified products were visualized in 2% agarose gels that ran at 3 V/ cm after staining with ethidium bromide.
In vitro MIC determination. The antimicrobial agents used in this study were selected on the basis of their licensing for treatment of swine dysentery in the United States. 3, 5, 6, 12, 14, 15, 20, 21, 38, 39 The MIC values of the synthetic antibacterial agent carbadox, d the polycationic aminoglycoside antibiotic gentamicin, e the lincosamide antibiotic lincomycin, f and the pleuromutilin antibiotic derivative tiamulin g against the porcine S. pilosicoli isolates were determined using the agar-dilution method. 14 The range of concentrations for each antimicrobial agent was selected on the basis of previous studies with S. hyodysenteriae and other porcine WBHIS. 14, 15, 38 Working concentrations of each antimicrobial agent were diluted in sterile distilled water, stored at Ϫ20 C, and used within 60 days. Petri dishes with quadrant divisions were used for the agar dilution MIC determinations. Each inoculum was prepared as a slurry containing approximately 10 5 colony forming units/ml by vortexing 0.2 ml of growth from a TSA-BB plate with 2.0 ml of trypticase soy broth and glass beads and inoculating a 50-l volume onto the medium. In each experiment, quadrants without antimicrobial agent and quadrants inoculated with S. hyodysenteriae isolate B204 were included as negative and positive controls, respectively. The plates were incubated at 42 C in a commercial anaerobic culture system a ; and the results were recorded after 4 days of incubation. All MIC determinations were done in a blind fashion. The MIC was determined as the lowest concentration of antimicrobial agent that inhibited spirochetal growth and hemolysis, and the median MIC of Ն3 separate experiments was determined for each isolate.
Results
Amplification of an S. pilosicoli-specific 16S rRNA gene sequence by PCR yielded products of approximately 361 bp with S. pilosicoli isolate P43/6/78 and the 19 field isolates. No amplification products were found in the absence of template DNA or with DNA from S. hyodysenteriae or S. innocens.
The MIC values of carbadox, gentamicin, lincomycin, and tiamulin against each S. pilosicoli isolate are presented in Table 2 . The distribution of MIC values for carbadox, gentamicin, lincomycin, and tiamulin, according to the country of origin of the isolates, are presented in Tables 3, 4 , 5, and 6, respectively. The MIC values of the reference isolate P43/6/78 were similar to those of the North American isolates of S. pilosicoli. The MIC values of the Canadian isolates were similar to those of isolates from the United States for all 4 antimicrobial agents. The MIC 50 and MIC 90 for each antimicrobial agent against the North American isolates of S. pilosicoli are presented in Table 7 . From available data on the in vitro antimicrobial susceptibility breakpoints of S. hyodysenteriae, 20,29 MIC breakpoints of each antimicrobial were estimated for intestinal spirochetes (Table 8) . From these estimates, it was determined that all of the isolates were susceptible to carbadox and tiamulin; the percentages of isolates susceptible, intermediate, and resistant to lincomycin were 42.1%, 42.1%, and 15.8% and to gentamicin were 47.4%, 0%, and 52.6%, respectively. cused on S. hyodysenteriae. 2, 8, 9, [14] [15] [16] [17] [20] [21] [22] 29, 30, 38, 39 Because S. pilosicoli was recognized only recently, little information is available about the in vitro antimicrobial susceptibility of this spirochete. 8, 9, 14, 21, 29, 30 The results of the present in vitro study indicated that 100% of the isolates were susceptible to carbadox and tiamulin, whereas the suceptibility to lincomycin and gentamicin differed among the isolates. None of the isolates were resistant to all 4 antimicrobial agents, but isolates UNL-53 and UNL-54, both from the same sampling on the same farm, were resistant to both lincomycin and gentamicin. Although resistance to carbadox and lincomycin has been reported with S. hyodysenteriae from Québec, 21 S. pilosicoli isolates from that region used in this study had MIC values similar to those of other North American isolates.
Discussion

Previous reports on the in vitro antimicrobial susceptibility of porcine intestinal spirochetes have fo-
Because the lowest concentration of carbadox tested by others 37 was 0.1 g/ml and the MIC 90 value for this antimicrobial agent against North American S. pilosicoli isolates was 0.015 g/ml, the MIC of carbadox against Australian S. pilosicoli probably was not achieved. Similarly, MIC for carbadox was not achieved with 3 Canadian and 6 American isolates of S. pilosicoli. Conversely, an MIC 90 of 0.10 g/ml was reported for 6 Swedish porcine S. pilosicoli isolates against carbadox, 8 a value that was higher than that found with the North American isolates. This finding is consistent with the MIC 90 of the North American isolates of S. pilosicoli against carbadox that were similar 8, [14] [15] [16] 38, 39 or much lower 21 than the MIC 90 of S. hyodysenteriae.
None of the porcine isolates of S. pilosicoli had MIC values Ͼ0.50 g/ml with tiamulin, and the MIC 50 and MIC 90 values were in agreement with those previously reported for 2 Australian 37 and 6 Swedish 8 porcine S. pilosicoli isolates. When compared with the MIC 90 of S. hyodysenteriae strains against tiamulin, the North American isolates of S. pilosicoli were similar. 2, 15, 16, 20, 21, 29, 30, 38 Thus, as previously shown for S. hyodysenteriae, 8, [15] [16] [17] 20, 21, 29, 30, 38 S. pilosicoli is highly sensitive to tiamulin.
In vitro MIC values of 1.0 g/ml have been reported for 2 porcine isolates of S. pilosicoli from Australia against lincomycin, 37 an MIC value approximately 50 times lower than the MIC 50 value determined for the North American isolates. The susceptibility of S. pilosicoli to gentamicin has not been previously determined. However, when compared with S. hyodysenteriae, the MIC 90 of North American S. pilosicoli isolates against lincomycin and gentamicin were similar. 2, [14] [15] [16] 20, 21, 29, 30, 38 Diarrheal disease and reduced performance associated with S. pilosicoli have been reported from all major swine producing countries of North America, Europe, and Australia. 1, 5, 6, 9, 10, 12, 19, [24] [25] [26] [27] [32] [33] [34] [35] [36] [37] The prevalence of S. pilosicoli infection in finisher farms of a multisite production system in the United States was estimated recently to be approximately 50%. 5 The results of in vitro antimicrobial susceptibility of North American isolates of porcine S. pilosicoli suggested that carba- Conversely, the susceptibility of the isolates to lincomycin and gentamicin was variable. Although field information on the clinical efficacies of the respective antimicrobial agents is consistent with the in vitro antimicrobial susceptibility results, controlled challenge studies would be helpful in making cost-effective recommendations on the applicability of specific antimicrobial agents for prevention or treatment of PCS. Monitoring of fecal shedding by cultures and PCR assays might help in making management decisions including strategic medication to reduce economic losses associated with PCS. 5, 10, 26 There were duplicate isolates recovered from 5 of the farms, and 3 of these pairs had MIC values that were different for 2 of the 4 antimicrobial agents tested, suggesting either technical variability in the method or multiple strains with different MIC values. The first possibility appears less likely because the MIC values were determined Ն3 times for each isolate and variability in the test alone could not account for the 10-fold differences observed in the MIC values of isolates UNL-51 and UNL-52 and isolates T9300098 and T9301604B for tiamulin. If the second possibility is found to be true, a decision to use an antimicrobial agent for control of PCS might require in vitro antimicrobial susceptibility testing of Ͼ1 isolate from the same farm. When response to treatment is poor, 1 or more of the following should be suspected as contributing factors: 1) other infectious or noninfectious causes of diarrhea, 2) error in dosage and/or inadequate delivery or uptake of antimicrobial agents, 3) poor control of environmental contamination with reinfection, and 4) antimicrobial resistance of the spirochete. Eradication of S. pilosicoli with antimicrobial therapy and sanitation, with or without depopulation, may be possible. Because the economic impact of PCS on swine production is not fully known, it might not be as cost effective to eradicate PCS as it is for the economically devastating swine dysentery. 38 Thorough laboratory diagnostic investigation is needed to correctly identify PCS and any other possible contributing etiologic factor(s) and devise appropriate control strategies.
Serpulina pilosicoli has a broader host range than does S. hyodysenteriae; spirochetes similar to S. pilosicoli have been seen in the intestines of human beings, nonhuman primates, dogs, guinea pigs, opossums, 1-Ͻ2 Ն2 * ND ϭ not determined. mice, and birds, often with clinical signs or lesions of colonic spirochetosis. 4, 7, 19, 23, 26, 35, 36 Because S. pilosicoli has been isolated from humans with lesions similar to PCS and human S. pilosicoli can colonize pigs and produce PCS, 35 it may be zoonotic and have public health significance. 7 Implementation of rational control measures to reduce infection by S. pilosicoli should improve overall animal health and productivity.
